Novavax, Inc. (NVAX) vs Vericel Corporation (VCEL)
- Novavax, Inc. NVAX 11.26 −12.17%
- Vericel Corporation VCEL 40.13 −2.17%
Novavax, Inc. and Vericel Corporation are both Biotechnology companies. Novavax, Inc. and Vericel Corporation are of similar size ($2.1B and $2.1B). Novavax, Inc. has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 83.6×. Vericel Corporation grew revenue faster over the last twelve months: 23.0% against −61.6%. Vericel Corporation has the higher net margin (7.91% vs −59.9%) and the higher return on invested capital (5.49% vs 0.00%). Across the 18 metrics below, Vericel Corporation leads on 11 and Novavax, Inc. on 7.
Valuation
Profitability
| Metric | NVAX | VCEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 78.60% | 74.56% | 65.16% |
| Operating margin | (56.58%) | 5.95% | 0.00% |
| Net margin | (59.87%) | 7.91% | 0.00% |
| Free cash flow margin | (10.20%) | 20.13% | 0.00% |
| Return on equity | 323.66% | 7.16% | (56.36%) |
| Return on assets | (21.62%) | 5.16% | (48.04%) |
| Return on invested capital | 0.00% | 5.49% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack